The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma
Open accessAbstract
BACKGROUNDMast cells are present in the airways of patients who have severe asthma despite glucocorticoid treatment; these cells are associated with disease characteristics including poor quality of life and inadequate asthma control.Stem cell factor and its receptor, KIT, are central to mast-cell homeostasis.We conducted a proof-ofprinciple trial to evaluate the effect of imatinib, a KIT inhibitor, on airway hyperresponsiveness, a physiological marker of severe asthma, as well as on airway mast-cell numbers and activation in patients with severe asthma. METHODSWe conducted a randomized, double-blind, placebo-controlled, 24-week trial of imatinib in patients with poorly controlled severe asthma who had airway hyperresponsiveness despite receiving maximal medical therapy.The primary end point was the change in airway hyperresponsiveness, measured as the concentration of methacholine required to decrease the forced expiratory volume in 1 second by 20% (PC 20 ).Patients also underwent bronchoscopy. RESULTSAmong the 62 patients who underwent randomization, imatinib treatment reduced airway hyperresponsiveness to a greater extent than did placebo.At 6 months, the methacholine PC 20 increased by a mean (±SD) of 1.73±0.60doubling doses in the imatinib group, as compared with 1.07±0.60doubling doses in the placebo group (P = 0.048).Imatinib also reduced levels of serum tryptase, a marker of mast-cell activation, to a greater extent than did placebo (decrease of 2.02±2.32 vs. 0.56±1.39ng per milliliter, P = 0.02).Airway mast-cell counts declined in both groups.Muscle cramps and hypophosphatemia were more common in the imatinib group than in the placebo group. CONCLUSIONSIn patients with severe asthma, imatinib decreased airway hyperresponsiveness, mastcell counts, and tryptase release.These results suggest that KIT-dependent processes and mast cells contribute to the pathobiologic basis of severe asthma.(Funded by the National Institutes of Health and others; ClinicalTrials.govnumber, NCT01097694.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.09.029 · Cited by 2,181
Measuring Quality of Life in Asthma
Juniper, E. F., Guyatt, G. H., Ferrie, P. J., & Griffith, L. E. (1993) · American Review of Respiratory Disease · doi:10.1164/ajrccm/147.4.832 · Cited by 887
Cited by
Severe and Difficult-to-Treat Asthma in Adults
Israel, E., & Reddel, H. K. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1608969 · Cited by 474
Self-citationMast Cells in Inflammation and Disease: Recent Progress and Ongoing Concerns
Galli, S. J., Gaudenzio, N., & Tsai, M. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-071719-094903 · Cited by 367
Diver, S., Khalfaoui, L., Emson, C., Wenzel, S. E., Menzies-Gow, A., Wechsler, M. E., Johnston, J., Molfino, N., Parnes, J. R., Megally, A., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00226-5 · Cited by 328
Self-citationCurrent Understanding of Asthma Pathogenesis and Biomarkers
Habib, N., Pasha, M. A., & Tang, D. D. (2022) · Cells · doi:10.3390/cells11172764 · Cited by 299
Mechanisms and therapeutic strategies for non‐T2 asthma
Sze, E., Bhalla, A., & Nair, P. (2020) · Allergy · doi:10.1111/all.13985 · Cited by 259
Metadata
- Authors
- Cahill, K. N., Katz, H. R., Cui, J., Lai, J., Kazani, S., Crosby-Thompson, A., Garofalo, D., Castro, M., Jarjour, N., DiMango, E., Erzurum, S., Trevor, J. L., Shenoy, K., Chinchilli, V. M., Wechsler, M. E., Laidlaw, T. M., Boyce, J. A., & Israel, E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-05-18
- Volume
- 376
- Issue
- 20
- Pages
- 1911-1920
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2615078498
- Cited by
- 212
- References
- 2
- FWCI
- 15.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma. https://app.cochat.ai/papers/10.1056/nejmoa1613125
- The paper
- Cahill, K. N., Katz, H. R., Cui, J., Lai, J., Kazani, S., Crosby-Thompson, A., Garofalo, D., Castro, M., Jarjour, N., DiMango, E., Erzurum, S., Trevor, J. L., Shenoy, K., Chinchilli, V. M., Wechsler, M. E., Laidlaw, T. M., Boyce, J. A., & Israel, E. (2017). KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1613125
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.